Condition
Erythema Nodosum Leprosum
Total Trials
5
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 2 (2)
P 4 (1)
Trial Status
Unknown2
Completed1
Not Yet Recruiting1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07172659Phase 2Not Yet RecruitingPrimary
Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction
NCT03775460Not ApplicableActive Not RecruitingPrimary
Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum
NCT04822909Phase 4CompletedPrimary
A Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum
NCT03807362Phase 2UnknownPrimary
CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum
NCT00406861Not ApplicableUnknownPrimary
Montelukast in ENL Reaction
Showing all 5 trials